drugset / Trial / NCT06255912
Clinical Trial for Advanced or Metastatic Pancreatic Cancer
Phase 2
Not yet recruiting
26 enrolled
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Non-randomizedSequentialQuadruple-blindTreatment
Summary
This is a Phase II clinical trial assessing the safety, tolerability, and pharmacokinetics of LTC004 in combination with MIL-97 ± chemotherapy in patients with advanced or metastatic pancreatic cancer. This experiment is divided into two parts: the dose increasing stage (stage 1) and the dose expanding stage (stage 2). For those enrolled in the planned expansion phase, the dose should have passed the safety assessment during the dose escalation phase.
Timeline
- Start
- 2024-03-01
- Primary completion
- 2029-03-01
- Completion
- 2031-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LTC004 | Unknown | 45 ug/kg | — |
| Subject | LTC004 | Unknown | 90 ug/kg | — |
| Subject | LTC004 | Unknown | 180 ug/kg | — |
| Background | MIL97 | Monoclonal antibody | 0.2 mg/kg | — |